Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Longitudinal ctdna tracking by low-pass whole-genome sequencing during CD19 CAR-T cell therapy for B-cell lymphomas

View Full Paper
Ask AI
Bookmark
Share

Authors

SZSijun ZhangYLYaqing LiFZFangrong Zong

Discussion

Loading...

Member takes

Overview

Observational study reveals treatment response and prognosis linked to ctDNA and residual disease in B-cell lymphomas.

Key Points

  • To evaluate low-pass whole-genome sequencing for tracking ctDNA and its relationship to treatment outcomes in B-cell lymphoma patients undergoing CD19 CAR-T therapy.
  • Included 11 patients with B-cell lymphomas receiving CD19 CAR-T therapy.
  • Peripheral blood samples were collected at baseline, one month, and three months post-infusion.
  • ctDNA levels were quantified using tumor fraction based on LP-WGS.
  • 1-year progression-free survival (PFS) rate was 64%; overall survival (OS) rate was 82%; event-free survival (EFS) rate was 45%.
  • Patients achieving complete response had lower baseline and peak tumor fraction values than those who didn’t.
  • Negative residual disease at baseline and one month showed better prognosis outcomes.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d56fhttps://doi.org/10.1182/blood-2025-7060
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy2024 · 20 citations
  2. 2Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) monitoring in diffuse-large B-cell lymphoma (DLBCL)2025
  3. 3Real-world evaluation of ctdna for risk stratification across the spectrum of both aggressive and indolent lymphomas2025 · 1 citations
  4. 4Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy2025
  5. 5Comprehensive analysis of early ctdna kinetics following first cycle of R-CHOP in LBCL patients2025